Expanding a Biopharmaceutical Technology Portfolio with Advanced Gene Therapeutics

Our Client & Their Goals

Our Client, a multinational biopharmaceutical company, had experience developing a wide range of successful products and treatments. However, they recognised that gene therapeutics represented an important sub-sector of the biopharmaceutical market that they couldn’t effectively address with their current technology portfolio. Our Client wanted to understand this unfamiliar competitive and technological terrain, and wanted to quickly obtain actionable advice on the best approach for their planned expansion into the area. They contacted CamIn seeking guidance on expanding into this new area.

CamIn's Solution

We worked with our Client’s research and development department to understand their specific goals for this strategic expansion. We then assembled a project team of twelve leading experts, each possessing expertise in a specific area of gene therapeutics that our Client intended to target in their expansion strategy. We performed a thorough investigation of this technology area, exploring 12 distinct sub-areas most relevant to their strategy and then determining those best to pursue. Our evaluation also identified the state-of-the-art technological solutions, their strengths and weaknesses, and the market potential of each of the technologies in each sub-area.

We first identified more than 110 technologies within our Client’s areas of interest. Then we provided a detailed evaluation of technologies that best fit our Client’s strategy for expansion and commercialisation.

The Impact

Our results, presented in a comprehensive report and workshop with our Client’s R&D team, provided them with the information and the advice they needed to expand into this new area. We first identified more than 110 technologies within our Client’s areas of interest. Then we provided a detailed evaluation of technologies that best fit our Client’s strategy for expansion and commercialisation. Our Client’s Head of R&D noted that our advice was “exactly what they wanted”. Their R&D head was also surprised that we could complete such high-quality work in such an “exceptionally short amount of time”—two months from the project’s start to its finish. 

Within six months of working with CamIn, our Client acquired one of the innovative biopharmaceutical companies that we had advised them to pursue. They have subsequently become a significant player in this fast-growing sub-sector of the biopharmaceutical industry.